AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03055078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
Study NCT03112187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
Study NCT03641560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide was administered orally
Study NCT03641560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
Study NCT04230850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Cupping
Description: One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
Study NCT02281253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fibre plus L-carnitine bread
Description: The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals.
Study NCT02281253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo bread
Description: The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
Study NCT04313764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% ESP block
Description: Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
Study NCT04313764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% infiltration
Description: Wound infiltration with 20 ml %0.25 bupivacaine
Study NCT04670107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib in combination with Immune checkpoint inhibitors
Description: Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
Study NCT00919113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% sodium chondroitin sulfate
Description: Weekly 20 mL Intravesical instillation
Study NCT03218488 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
Study NCT04230850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
Study NCT03411603 — intervention group
Intervention type: OTHER
Intervention: Diet and socio-demographic questionnaires
Description: 24-hr recall or food diary questionnaires; socio-demographic questionnaires
Study NCT00121732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7974
Description: Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
Study NCT00121732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7974
Description: Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
Study NCT02755896 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Arm 1 600 cGY x 5 fractions
Description: Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
Study NCT02755896 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Arm 2 800 cGY x 3 fractions
Description: Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
Study NCT03532139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
Study NCT03532139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin + Rosuvastatin
Description: Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
Study NCT03532139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis
Description: standard of care therapy
Study NCT03712605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care observation
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT or CT
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET-CT or CT
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00919113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The identical buffer used in Uracyst for the same administration
Study NCT03316963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Methylsulfate
Description: After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
Study NCT04624360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
Study NCT04624360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2cc 0.9% Saline
Study NCT04006808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PED-HZ/su
Description: GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
Study NCT01695239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03712605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT03712605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT03712605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03712605 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04637009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS1553
Description: Form: tablet; Route of Administration: oral
Study NCT05148520 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 5A's model
Description: (1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~- arrange for follow-up.
Study NCT03609398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVF Vaccine
Description: 1.0 mL dose given SQ in upper arm
Study NCT01568801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SingaPACE
Description: Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
Study NCT03636698 — intervention group
Intervention type: OTHER
Intervention: chorioamnionitis
Description: It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
Study NCT00356837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: use ultrasound to confirm diagnosis of extremity fractures
Study NCT02616601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Fluorouracil Cream
Description: Topical cream, generic formulation of the brand product.
Study NCT02616601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carac® (Fluorouracil) Cream
Description: Topical cream, brand product.
Study NCT02616601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Topical cream, placebo. Has no active ingredient.
Study NCT04137510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
Study NCT04137510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
Study NCT05387330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA kit
Description: Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
Study NCT03718403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline will be given to maintain a peak level between 10-15 mcg/mL
Study NCT01333566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 500 mg/m² every 3 weeks
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m² every 3 weeks
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m² every 3 weeks
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride
Description: 100 mg/m² every 3 weeks
Study NCT01333566 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control Group
Description: Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: 100 mg/m² every 3 weeks
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 500 mg/m² every 3 weeks
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 500 mg/m² every 3 weeks
Study NCT00630032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: 40 mg/m² every 3 weeks
Study NCT00201201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
Study NCT00201201 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control group receiving care as usual after interfacing with the surveys on the PEP-NG
Study NCT01435512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD-Focused CBT for Partner Violence
Description: PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
Study NCT04557137 — intervention group
Intervention type: DRUG
Intervention: Somatostatin analog
Description: 120 mg ipstyl every 28 days
Study NCT02979054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4020
Study NCT02979054 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03521804 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SoundBite™ Crossing System Active Wire 14
Description: Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
Study NCT01899287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group education
Description: The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse.
Study NCT02968290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
Study NCT02968290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon AcrySof SA60AT
Description: Implant of intraocular lens hydrophobic
Study NCT02968290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch Lomb AkreosA
Description: Implant of intraocular lens hydrophilic
Study NCT04456283 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survival
Description: 5 year survival after Chemoradiation theraphy for Rectal Cancer
Study NCT04878926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
Description: IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
Study NCT04878926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV midazolam and propofol-based sedation with Local Anesthetic infiltration
Description: IV midazolam and propofol-based sedation with Local Anesthetic infiltration
Study NCT01975649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tribulus Terrestris
Description: patients will use 750 mg/day during 120 days
Study NCT01975649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will use placebo pills with the same shape of the drug
Study NCT00585169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: 10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
Study NCT05670340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Switched Prosthetic Profile
Description: The implant will be rehabilitated with a switched emergence profile
Study NCT05670340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Matched Prosthetic Profile
Description: The implant will be rehabilitated with a matched emergence profile
Study NCT01530256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: 160 mg IV q 4 weeks for 4 doses
Study NCT01530256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: 320 mg IV q 4 weeks for 4 doses
Study NCT01530256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD518
Description: 640 mg IV q 4 weeks for 2 doses
Study NCT01272622 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
Study NCT01272622 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wait and watch
Description: wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
Study NCT05509673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipofilling (sublesional fat grafting)
Study NCT04287647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transpyloric stent
Description: See arm/group descriptions
Study NCT04287647 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study NCT00153920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT02719860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: 4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
Study NCT02719860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black tea
Description: 4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
Study NCT02719860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
Study NCT01067911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola
Description: Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
Study NCT01067911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter
Description: Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.